INTRODUCTION
The first successful umbilical cord blood (UCB) transplantation was performed in 1988 [1] , and since that time, the ability to cryopreserve and bank UCB units has remained an essential component of their use in hematopoietic stem cell transplantation. The use of UCB as a donor source has continued to grow, and there are currently over one half a million UCB units cryopreserved in the worldwide cord blood inventory [2] .
Although cryopreservation is universally practiced in cord blood banking, the impact on progenitor cell function has been only partially addressed. Broxmeyer et al. demonstrated that UCB units stored for up to 20 years do not lose function when used in vitro and in murine assays of progenitor cell function [3, 4] , and the St. Louis group reported no significant influence on clinical outcome after short-term cryopreservation [5] . Parmar et al. recently reported on clinical outcomes for cryopreserved units, but they only documented 15 UCB units older than 5 years [6] . Hence, there is still no conclusive answer to the question of whether longterm cryopreservation affects UCB transplantation outcomes. Storage of UCB units comes at a financial cost to cord blood banks [7, 8] , which is ultimately passed on to the patient, transplantation institution, and the health care system as a whole [9] [10] [11] . If long-term cryopreservation is detrimental to UCB transplantation outcomes, the current model of cord blood banking must be called into question. Alternatively, if the duration of cryopreservation has no impact on clinical outcomes, this provides evidence for cord blood banks to continue the current model of cryopreservation, long-term storage, and distribution of UCB units, to provide a rapidly accessible donor source for transplant recipients worldwide.
In this study, we set out to determine whether duration of cryopreservation influenced single UCB transplantation outcomes. We also examined the effect of cryopreservation on post-thaw UCB unit characteristics.
METHODS

Study Design
This was a retrospective review of 416 patients who underwent single UCB transplantation at the University of Minnesota between 1992 and 2013. Reasons for exclusion from the analysis included no available date of Biology of Blood and Marrow Transplantation j o u r n a l h o m e p a g e : w w w . b b m t . o r g collection for the UCB unit (n ¼ 125) and patients who did not receive conditioning before receiving the UCB unit (n ¼ 3). Patients were treated on protocols approved by the University of Minnesota institutional review board, and written consent was obtained from all patients, their parents, or guardians in accordance with the Declaration of Helsinki.
UCB Unit Processing
On delivery of UCB units to the University of Minnesota Molecular and Cellular Therapeutics facility, units were inspected and then transferred and maintained in vapor phase of liquid nitrogen storage until the day of infusion. All UCB units were thawed and washed per the method of Rubinstein et al. [12] . Before the wash, ABO/Rh typing of the unit was performed. After the wash and before release for infusion, samples were taken for assessment of viability, total nucleated cell dose (TNC), CD34
þ dose, and colony-forming units-granulocyte macrophage (CFU-GM). Viability was assessed using the acridine orange and propidium iodide method [13] and 7-aminoactinomycin D (by flow cytometry). Flow cytometry was performed as per the International Society of Hematotherapy and Graft Engineering specifications using a dual platform, with ammonium chloride lysis for red cells followed by washing and staining.
Definitions and Outcome Analysis UCB units were analyzed based on the duration of cryopreservation of the UCB unit. The TNC recovery was defined as the total TNC recovered at thaw, expressed as a percentage of the total TNC count reported before freezing.
Neutrophil and platelet engraftment were defined as previously described [14] [15] [16] . Cox regression analysis was used to perform univariate and multivariate analysis of patient and UCB unit factors and their influence on outcomes. The following variables were assessed for their association with neutrophil and platelet engraftment: duration of cryopreservation, post-thaw TNC/kg, post-thaw CD34 þ /kg, viability post-thaw, post-thaw CFU/kg, UCB unit-recipient ABO match, UCB unit-recipient HLA match, year of transplantation, type of conditioning regimen used, recipient gender, recipient age, and recipient cytomegalovirus status. After 2005, patients undergoing UCB transplantation at the University of Minnesota have not routinely received antithymocyte globulin as part of their myeloablative conditioning regimen. As such, year of transplantation was examined as patients who underwent hematopoietic stem cell transplantation before 2006 compared with the more recent era.
RESULTS
Cell Recovery
There were 288 single UCB transplantations eligible for analysis, with the duration of cryopreservation of the UCB units ranging from .08 to 11.07 years ( Figure 1 cells. The median post-thaw nucleated cell viability for the cohort was 72% (range, 30% to 94%) and median post-thaw total CFU-GM was 1.1 Â 10 6 (range, 0 to 58.81). The median TNC recovery was 76% (range, 30% to 108%). Duration of cryopreservation of the UCB unit had no significant impact on the median post-thaw TNC (P ¼ .22), CD34 þ (P ¼ .28), or CFU-GM (P ¼ .68). Duration of cryopreservation of the UCB unit also had no impact on post-thaw nucleated cell viability and TNC recovery (Figure 2A ,B).
Neutrophil Engraftment
Neutrophil engraftment for the cohort was 94% (95% confidence interval, 91% to 96%), with a median time to neutrophil recovery of 20 days (range, 0 to 41). When duration of cryopreservation of the UCB unit was analyzed as a continuous variable in multivariate analysis, there was no impact on neutrophil engraftment (P ¼ .15, data not shown). UCB units were also analyzed in tertiles based on time spent in cryopreservation (0 to 2 years, 2.1 to 4 years, >4 years) and tested in univariate (Table 1 ) and multivariate analysis ( Table 2 ). There was no association of duration of cryopreservation on the probability of neutrophil engraftment. Other covariates, including CD34 þ dose, CFU-GM, and year of transplantation were independently significant factors identified in multivariate analysis ( Table 2) . Duration of cryopreservation of the UCB unit also had no significant impact on time to neutrophil engraftment ( Figure 3A ).
Platelet Engraftment
Platelet engraftment at 1 year was 74% for the cohort (95% confidence interval, 67% to 81%), with a median time to platelet recovery of 48 days (range, 10 to 224). When analyzed as a continuous variable in multivariate analysis, duration of cryopreservation of the UCB unit had no impact on platelet engraftment at 1 year (P ¼ .94, data not shown). Duration of cryopreservation of the UCB unit also had no significance when analyzed in tertiles in univariate and multivariate analysis (Tables 3 and 4 ). The only covariate that was significantly associated with platelet engraftment in the multivariate analysis was CFU-GM (Table 2B) . Although the time to platelet engraftment was significantly different based on duration of cryopreservation of the UCB unit (P ¼ .03), this was driven by delayed recovery in the UCB units cryopreserved for 4.1 to 5 years compared with units cryopreserved for shorter or longer time periods. Thus, there was no prolongation of time to platelet engraftment based on the duration of cryopreservation ( Figure 3B ).
DISCUSSION
In this study, we examined the engraftment capacity and kinetics of UCB units that were collected and stored for up to 12 years before use. We found that duration of storage, however, had no obvious impact on cellular recovery or engraftment after UCB transplantation. These results are in line with preclinical studies published by Broxmeyer et al. [3, 4] , as well a recent small clinical study [6] , and support the use of cryopreserved UCB as a reliable, rapidly accessible donor source. Each UCB unit collected by cord blood banks increases the available donor pool, in contrast to the pool of unrelated donors, which is subject to ongoing donor attrition [ 17, 18] . As the pool of available UCB units grows, it will continue to make UCB transplantation more accessible, particularly for minority groups [19] .
The characteristics of the UCB unit are vital to successful transplantation [20] [21] [22] [23] [24] [25] . In this study, we also demonstrate that the length of cryopreservation did not significantly affect viability, TNC recovery, or CFU-GM analysis in a clinical laboratory, which is supported by previous studies performed in research laboratories [3, 4] . These results question the cord bank practice of considering UCB units outdated after 10 years [26] and the general practice of avoiding older UCB units for fear of poor clinical results. Thus, our study provides further evidence that long-term cryopreservation of UCB units is not detrimental to outcomes and suggests that each UCB unit should be assessed on its individual characteristics (HLA match, TNC, CD34 þ , etc.) but not on the duration of cryopreservation of the unit.
One of the limitations of this study is the heterogeneous nature of the patient population, which did not allow us to compare outcomes in relation to graft-versus-host disease, transplantation-related mortality, relapse, or survival. Our study also included relatively few UCB units that had been cryopreserved for >10 years, which makes it is difficult to extrapolate the conclusions to UCB units that have been cryopreserved for more than a decade. It must be stated, however, that there is no evidence to contradict the use of UCB units older than 10 years, and preclinical data suggest that these products remain viable and potent [4] . In reviewing UCB unit characteristics, it was not possible to analyze recovery of CD34 þ or CFU after cryopreservation, as the heterogeneous nature of measurement techniques used at different cord collection centers makes it impossible to accurately compare the different prefreeze values. There were also a significant number of UCB units that did not have a date of collection (n ¼ 125) and so had to be omitted from the analysis. However, almost all of these units were collected and subsequently used in the earliest years of UCB transplantation, without undergoing long-term cryopreservation, and so they would not have contributed to the data set in a meaningful way. Our study also excluded units used in double UCB transplantations, as this removed UCB unit interaction as a potential confounding factor in our analysis. Hence, the impact of long-term cryopreservation of the UCB unit in double UCB transplantation remains unclear.
Our study demonstrated that the amount of time a UCB unit spends in cryopreservation, up to 10 years, has no significant impact on engraftment outcomes. These results support the use of UCB units that have undergone long-term cryopreservation and should provide reassurance to clinicians in the field of UCB transplantation.
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